Evidence map›Paper›PMID 42461965›Full record

ArticlePLoS pathogens2026

The antiviral GTPase MxB is packaged into virions and binds via its N-terminal domain to alphaherpesvirus capsids.

Sebastian Weigang, Manutea C Serrero, Boris Bogdanow, Franziska Hüsers, Julia Lückel, Rudolf Bauerfeind, Fan Liu, Georg Kochs, Beate Sodeik

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sebastian WeigangInstitute of Virology, Freiburg University Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-8415-6920
Manutea C SerreroInstitute of Virology, Hannover Medical School, Hannover, Germany.
Boris BogdanowDepartment of Structural Biology, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.
Franziska HüsersInstitute of Virology, Hannover Medical School, Hannover, Germany.
Julia LückelInstitute of Virology, Freiburg University Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Rudolf BauerfeindResearch Core Unit Laser Microscopy, Hannover Medical School, Hannover, Germany.
Fan LiuDepartment of Structural Biology, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.
Georg KochsInstitute of Virology, Freiburg University Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0003-0187-559X
Beate SodeikInstitute of Virology, Hannover Medical School, Hannover, Germany.ORCID 0000-0003-4650-3036

Funding

Center for Infection Biology (ZIB)German Research Foundation (Deutsche Forschungsgemeinschaft)Germany’s Excellence Strategy EXC2155 RESISTThe Hannover Biomedical Research School (HBRS)Virology, University Hospital Freiburg
6 · The paper itself

Abstract

The interferon-inducible myxovirus resistance proteins (Mx) belong to the dynamin-like GTPases; MxA is a restriction factor against several RNA viruses, while MxB restricts infections of lentiviruses and herpesviruses. Humans express MxA(1-662) with an N-terminal domain (NTD) of 43 residues, MxB(1-715) with an NTD of 91 residues, and a truncated MxB(26-715) with an NTD of 66 residues. Although the roles of the GTPase and stalk domains during infection are increasingly being elucidated, the functions of the different NTDs remain poorly understood. Using cell lines stably expressing Mx proteins, we show that MxB(1-715), but not MxA, inhibited infection by herpes simplex virus (HSV-1) and pseudorabies virus (PrV). Quantitative mass spectrometry and subviral fractionation experiments indicate that MxB(1-715), but not the truncated MxB(26-715) or MxA(1-662), was enriched in the tegument of HSV-1 and PrV virions. Moreover, dimeric, recombinant, chimeric proteins with the NTD peptides MxB(1-91) or MxB(1-35), and to a lesser extent MxB(26-91), bound to tegumented HSV-1 capsids, while MxA(1-43) did not. In contrast, de-tegumented HSV-1 and PrV capsids bound to proteins with MxB(1-91), but not to those with MxB(1-35) or MxA(1-43). Our findings indicate that the NTD of MxB is crucial to restrict HSV-1 and PrV infections, that newly assembled virions package MxB into the tegument around the capsid, and that both the N-terminal MxB amino acid residues 1-25 and 26-91 contribute to its binding to tegumented and de-tegumented herpesviral capsids.

Indexed as

CapsidHerpesvirus 1, HumanHerpesvirus 1, SuidMyxovirus Resistance ProteinsVirionVirus AssemblyAnimalsHumansProtein DomainsMX2 protein, humanMyxovirus Resistance Proteins

Identifiers

PMID42461965
PMCPMC13374926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.